Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P5TG
|
||||
| Former ID |
DIB011819
|
||||
| Drug Name |
Multi-epitope peptide melanoma vaccine
|
||||
| Synonyms |
Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | Melanoma [ICD9: 172; ICD10:C43] | Phase 3 | [1] | ||
| Company |
University of Pittsburgh
|
||||
| Target and Pathway | |||||
| Target(s) | MART-1 melanoma antigen | Target Info | [2] | ||
| Melanocytes lineage-specific antigen GP100 | Target Info | [2] | |||
| Tyrosine oxidase | Target Info | [2] | |||
| BioCyc Pathway | (S)-reticuline biosynthesis | ||||
| Eumelanin biosynthesis | |||||
| L-dopachrome biosynthesis | |||||
| KEGG Pathway | Tyrosine metabolism | ||||
| Riboflavin metabolism | |||||
| Metabolic pathways | |||||
| Melanogenesis | |||||
| PathWhiz Pathway | Riboflavin Metabolism | ||||
| Tyrosine Metabolism | |||||
| WikiPathways | Dopamine metabolism | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health. | ||||
| REF 2 | Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.